CARDIOVASCULAR ABNORMALITIES IN PATIENTS WITH HIV INFECTION: A BOLT IN BLUE

Anita Arya1, Ashish Deshmukh2, Kaustubh Dilip Mundada3

1Associate Professor, Department of Medicine, Gandhi Medical College, Bhopal.
2Senior Resident, Department of Medicine, Gandhi Medical College, Bhopal.
33rd Year Resident, Department of Medicine, Gandhi Medical College, Bhopal.

ABSTRACT

One of the consistent findings among various studies on HIV has been simultaneous multiorgan dysfunction. Cardiovascular disorders are now most common cause of mortality worldwide. With more effective and widespread treatment of HIV in resource-rich settings, morbidity and mortality from non-AIDS-related events have surpassed those from AIDS-related events with cardiovascular diseases emerging as an important cause of death in HIV-infected patients relative to the decreasing incidence of opportunistic disease. Various studies have reported a 1.5-fold increase in the rate of cardiovascular events in HIV-infected individuals compared to control populations.

MATERIAL AND METHODS

The aim of the study was to find the prevalence and types of different cardiovascular abnormalities in HIV positive patients and assess their association with CD4 counts. Consecutive 82 patients, HIV positive patients fulfilling the inclusion criteria and giving informed consent were included in the study. All patients were subjected to history taking and a detailed physical examination. Blood counts, renal function tests, lipid profile and CD4 counts were estimated and patients were subjected to 12-lead ECG, chest X-ray and 2D/Colour Doppler Echocardiogram.

RESULTS

Of the 82 patients studied 47.46% had evidence of cardiovascular involvement, out of which 12% had clinical features of heart failure while electrocardiographic changes were seen in 35% of patients in the form of sinus tachycardia (27%), QTc prolongation (10%) and left sided chamber enlargements (6%). Echocardiographic abnormalities were noted in 39 patients (47.56%) including fractional shortening associated with systolic dysfunction (26.8%). The mean CD4 count in patients with echocardiographic abnormalities was found to be 58.87±29.80, whereas in patients without echocardiographic abnormalities it was 136.53±38.80 (p<0.0001).

CONCLUSION

High frequencies of cardiac abnormalities, both symptomatic and asymptomatic were detected in the HIV/AIDS patients in our study. Furthermore, the study concluded that a careful initial and periodic cardiac evaluation to detect early involvement of the cardiovascular system in the HIV disease is recommended. Since the HIV-infected population is relatively young and actual cardiovascular events are infrequent, more long terms studies are needed.

KEYWORDS

HIV, CD4 Counts, Cardiovascular Abnormalities.


INTRODUCTION

HIV/AIDS is a multisystemic disease, affecting virtually every organ and system of the body and causing progressive dysfunction. Cardiac involvement impacts on the natural history and prognosis of the HIV disease. Of interest is the observation that the incidence of AIDS-related heart disease found in post-mortem studies is significantly higher than the incidence of abnormalities diagnosed clinically ante-mortem. Therefore, it is possible that many AIDS patients have cardiac abnormalities that are not recognized during the course of their illness.

In an autopsy study carried out in 1998, cardiac abnormalities were noted in two-thirds of the patients with AIDS. These abnormalities, which were attributed directly or indirectly to the HIV virus and/or treatment side effects, could largely have been detected early ante-mortem using echocardiography, a non-invasive radiation-free investigation.

Despite the availability of many single centre and multicentre reports a clear picture of how cardiovascular disease manifests in patients with HIV/AIDS is confounded in most available studies coming from developed countries by the presence of several comorbidities and prolonged history of drug intake. Considering the ever increasing population of HIV positives in our country and the significant causal relationship with cardiovascular abnormalities established by current literature, this study was undertaken to identify cardiovascular abnormalities in treatment-naïve patients in order to assess the cardiac effects of HIV infection while excluding drug effect.
MATERIAL AND METHODS
This prospective study was conducted among HIV patients reporting to Anti Retroviral Therapy Center of Gandhi Medical College and associated Hamidia Hospital, Bhopal. The aim of the study was to find the incidence and types of cardiovascular abnormalities in HIV infection, to study the association between cardiovascular abnormalities and CD4 count. Inclusion criteria for the study were HIV-infected patients whose age more than 15 years, who are antiretroviral therapy (ART)-naïve and without any history or examination suggestive of ischemic, rheumatic, congenital, diabetic or hypertensive heart disease.

Eighty two HIV positive patients presenting to ART centre and fulfilling the above criteria were included in this study. All patients were subjected to a detailed history taking and a thorough physical examination. The CD4 counts were estimated along with other routine laboratory investigations like complete blood counts, renal function tests, lipid profile and fasting blood sugars. Patients then underwent screening with chest x-ray, 12-lead ECG and 2D and Color Doppler Echocardiogram.

RESULTS
A total of 82 HIV positive patients were studied, of which 63 were males and 19 females. The age ranged from 22 to 56 yrs. and the mean age was 34 yrs. Out of these 82 patients, 39 i.e. 47.56% had evidence of cardiovascular abnormalities. Most common cardiovascular abnormality found was systolic dysfunction 22(26.8%), followed by pericardial effusion 17(21%), dilated cardiomyopathy with global hypokinesia 5(6%), infective endocarditis 1(1.2%). The predominant mode of presentation was dyspnea; 43% of patients had evidence of cardiovascular involvement in the form of ECG changes as depicted in Fig 1.

Echocardiographic abnormalities were noted in 39 patients (47.56%). As shown in Fig 2, most common echocardiographic abnormality found was reduction in fractional shortening associated with systolic dysfunction (n=22, 26.8%) and dilated cardiomyopathy (n=5, 6%) followed by left ventricular diastolic dysfunction (8 patients, 10%), and pericardial effusion (17 patients, 21%). While the pericardial effusions noted were small and asymptomatic, all patients with left ventricular diastolic dysfunction (8/10%) had Grade 1 diastolic dysfunction. Many of the patients presented with multiple abnormalities, which were shown in Fig 2.

Increased left atrial dimension (>40mm) is seen in 5 (6%) of patients. The mean left atrial dimension for patients having LV dysfunction and those without LV dysfunction is 33.63mm and 29.8mm respectively. Also increased RVD was seen in 6(7%) patients.

Increased left ventricular end diastolic dimension (>56mm) is seen in 5(6%) patients. The mean left ventricular end diastolic dimension for patients having LV dysfunction and those without LV dysfunction is 50.51mm and 42.55mm respectively.

Increased left ventricular end systolic dimension (>39mm) is seen in 12(14%) patients with LV dysfunction. The mean left ventricular end systolic dimension for patients having LV dysfunction and those without LV dysfunction is 37.52mm and 27.97mm respectively. Diastolic dysfunction was present in 8(10%) patients, which was grade one in all these patients. These patients had E/A ratio less than 1.

In the present study, left ventricular ejection fraction was less than 55% in 22(26.8%) of patients. The mean EF for patients having LV dysfunction and those without LV dysfunction was 43.68±4.10% and 64.38±3.48% respectively. Fractional shortening less than 28% was seen in 22(26.8%) patients. The mean fractional shortening for patients having LV dysfunction and those without LV dysfunction are 22.29% and 33.86% respectively. The range was 30.76±0.77%.

CD4 count was less than 100 per cu mm in 26(31.7%) patients having echocardiographic abnormalities; 13(12%) patients having echocardiographic abnormalities had CD4 count more than 100 per cu mm; 31(37%) patients without echocardiographic abnormalities had CD4 count less than 100 per cu mm while 12(14.6%) patients had CD4 count more than 100 per cu mm. Mean CD4 count in patients with echocardiographic abnormalities was found to be 58.87±29.80, whereas in patients without echocardiographic abnormalities it was 136.53±38.80 (P<.001) (Table 1).

DISCUSSION
The degree to which HIV infection itself, traditional cardiovascular risk factors and ART each contribute to the elevated risk of cardiovascular disease in the HIV-infected population are unknown. In our study, we included only those patients who were not on antiretroviral therapy and found that the prevalence of cardiac abnormalities to be 47.56%, which is far higher than previous studies evaluating this by PAggrawal etal, but quite close to 50% prevalence seen in study by Hakim et al. In our study, we also found that patients with CD4 count <100/mm^3 had a high prevalence of cardiovascular abnormalities than those with CD4 counts >100/mm^3, which was similar to study done by Klein D et al.1

With more effective and widespread treatment of HIV in resource-rich settings, morbidity and mortality from non-AIDS-related events have surpassed those from AIDS-related events.2-4 In particular, cardiovascular disease has emerged as an important cause of death in HIV-infected patients relative to the decreasing incidence of opportunistic disease.

Various studies have consistently reported a 1.5-fold increase in the rate of cardiovascular events in HIV-infected individuals compared to control populations, although some of these studies are limited by low number of events, short follow-up and incomplete assessments of other cardiac risk factors.5-9 Overall, the classic cardiovascular risk factors of dyslipidemia, hypertension, diabetes and smoking are common among HIV-infected populations, although the frequency of these comorbidities is not sufficient to explain the overall increased incidence of cardiovascular disease observed in the setting of HIV infection.

This higher risk of CVD in HIV-infected patients than the general population originates from the development of atherosclerosis, which seems to be multifactorial in origin, related to the higher rates of smoking, dyslipidemia and other traditional risk factors in the HIV-infected population and the virus itself causing a chronic inflammatory state, which leads to endothelial dysfunction and atherosclerosis and also seems to be related to cART and the biological changes it causes. Compared with uninfected controls, HIV-infected individuals more frequently have low high-density lipoprotein cholesterol (HDL–c) and elevated triglycerides. Despite possible contributions of some ART drugs (Most studies implicate old protease inhibitors and this does not seem like a class effect).
On cardiovascular risk, several studies suggest that higher CD4 cell counts and lower HIV RNA levels are associated with decreased MI risk. Discontinuation of ART is associated with an even greater risk of cardiovascular events suggesting a protective effect of suppression of HIV replication. Premature coronary artery pathology has been reported among HIV-positive individuals. Autopsy studies first suggested an association between vascular endothelial pathology and HIV. Reporting of clinically evident Coronary Artery Disease (CAD) has increased since the introduction of PIs in 1996. HIV infection was associated with a greater risk of acute MI overall, even after adjusting for Framingham risk factors and other comorbidities (Adjusted HR 1.48, 95% CI 1.27-1.72).

HIV infected patients have higher rates of MI than non-HIV infected patients, 11.13 versus 6.98 per 1000 person-years in a recent US study. A recent Danish study found that HIV infected patients receiving Highly Active Antiretroviral Therapy (HAART) were more likely to be hospitalized with ischemic heart disease than HIV-uninfected controls. Similarly, a Kaiser Permanente study found a higher rate of cardiovascular events in HIV infected patients who were not receiving ARV therapy compared to HIV uninfected controls.

Left ventricular dysfunction, dilated cardiomyopathy, and myocarditis all occur with increased frequency in AIDS patients. In a pre-HAART study, global LV hypokinesis was found in 14.5% of patients and was associated with lower CD4 counts and congestive heart failure was diagnosed in about 2% of patients. Causes may include a direct effect of HIV, other cardiotropic viruses, ARV toxicity, cytokines, opportunistic infections (OIs), illicit drug use or nutritional deficiencies. In a pre-HAART series of myocardial biopsies in HIV patients, 5 of 33 stained positive for HIV, while 16 of 33 were positive for CMV using antisense riboprobes. The incidence of cardiomyopathy is declining post-HAART.

Myocarditis has many causes in HIV-infected patients, though a specific diagnosis is rare. These include toxoplasmosis, tuberculosis, Cryptococcus neoformans, Aspergillus, Candida, cytomegalovirus, HSV, Mycobacterium avium-intracellulare, and HIV. In an Italian study, lymphocytic interstitial myocarditis was documented in 30 of 440(7%) of AIDS patients at autopsy. Again, the incidence of myocarditis has also declined in the era of effective HIV treatment.

Pericardial disease is common in HIV-infected patients. In the Prospective Evaluation of Cardiac Involvement in AIDS (PRECIA) study, before the introduction of HAART the incidence of pericardial effusion was 11% per year and it was associated with shorter survival and lower CD4 counts. A majority of the effusions were asymptomatic and idiopathic. They rarely cause tamponade. Various OIs and malignancies have been reported to cause pericardial effusions including Kaposi’s sarcoma, mycobacteria, CMV, prosthetic valve endocarditis, bacterial pericarditis caused by organisms such as Streptococcus pneumonia. Nocardia, lymphoma and immune reconstitution inflammatory syndrome secondary to Mycobacterium tuberculosis (TB).

In Africa, the majority of pericardial disease in HIV infected patients is caused by TB. The incidence of pericarditis has also been decreasing since the introduction of HAART.

In a retrospective study of the incidence of cardiac disease comparing the era of mono or dual NRTI therapy versus HAART, the incidence of pericarditis had decreased from 13.5% to 3.4%. Bundle branch block, atrial fibrillation, ischemia and dilated cardiomyopathy have similarly decreased.

It is unknown if the incidence of pericardial effusion has declined in the HAART era. However, the direct effects of HIV and OIs on cardiovascular tissue and the associated cardiac disease have been significantly reduced as a result of effective HIV treatment.

Thromboembolic disease has a high prevalence in HIV-infected patients, including deep vein thrombosis, pulmonary embolism, thrombotic microangiopathy and retinal venous thrombosis. A retrospective review found a rate of deep venous thrombosis ten times that of HIV-uninfected patients in the general population. Thromboembolic events have been found to occur at higher rates in patients with a CD4 count <200/mm3 compared to those with a CD4 >200/mm3.

Fultz et al. looked a 37,535 HIV-infected veterans and the same number of controls and found an increased rate of venous thromboembolism in the HIV-infected veterans, both before 1996 in the pre-HAART era and after 1996 in the HAART era after protease inhibitors became available for treatment. A study by Liljering et al. found that patients with CD4 <200/mm3 had higher factor VIII and fibrinogen concentrations and lower protein S concentrations, perhaps explaining some of the difference in thrombosis rates. Other factors underlying thromboembolic events in HIV infected patients are discussed in a previous section of this paper.

Pulmonary hypertension is significantly increased in HIV infected patients compared to the general population with an incidence of around 0.5% reported in 1991. The same incidence (0.46%) was found in a 2008 study, thus refuting the hypothesis that the incidence had decreased since the introduction of HAART. Though HAART improved mortality in HIV-infected patients with pulmonary hypertension in a prospective study of the Swiss HIV Cohort, the median survival was poor at 2.7 years from diagnosis.

Therefore, pulmonary hypertension portends a poorer prognosis in HIV-infected patients, despite HAART therapy.

The rates of endocarditis are similar among HIV-infected patients with shared risk factors, such as injection drug use and non-HIV-infected individuals. HIV per se does not seem to be a risk factor for endocarditis, though mortality may be higher for those with CD4 counts under 200/mm3. Finally, cardiac neoplasms are a rare complication of AIDS. B cell lymphomas can be primary cardiac lymphomas or part of disseminated disease. Kaposi’s sarcoma can rarely invade the heart in disseminated disease. Both of these neoplasms are more common in HIV-infected than in HIV uninfected patients.

The full extent of cardiovascular risk in treated HIV-infected patients will become more discernible as more studies continue to follow patients over time. Since the HIV-infected population is relatively young and actual cardiovascular events are infrequent, many investigators are now using surrogate measures of coronary artery disease, such as coronary artery calcium scoring, carotid intimal medial thickness and flow mediated dilatation as indirect endpoints.

In view of the high frequency of cardiac abnormalities detected in the HIV/AIDS patients in our study and well established risk of cardiovascular diseases in HIV patients, it is...
suggested that HIV-positive patients should have a careful initial and periodic cardiac evaluation and risk stratification to detect early involvement of the heart in the HIV disease.

REFERENCES


### Table 1

<table>
<thead>
<tr>
<th>CD4 Count</th>
<th>Echocardiographic Abnormalities</th>
<th>Present</th>
<th>Absent</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Frequency</strong></td>
<td><strong>Percentage</strong></td>
<td><strong>Frequency</strong></td>
</tr>
<tr>
<td>&lt;100 cu mm</td>
<td>26</td>
<td>31.7</td>
<td>31</td>
</tr>
<tr>
<td>&gt;100 cu mm</td>
<td>13</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>Mean CD4 count with SD</td>
<td>58.87±29.80</td>
<td>136.53±38.80</td>
<td></td>
</tr>
</tbody>
</table>